Skip to main content
. 2022 Jan 20;298(3):101608. doi: 10.1016/j.jbc.2022.101608

Figure 7.

Figure 7

DpC treatment decreases the expression of TnC, β-catenin, and YAP/TAZ in orthotopic pancreatic cancer (PC) tumors in nude mice. Mice orthotopically implanted in the pancreas with a 1:1 mixture of AsPC-1-luc PC cells and pancreatic stellate cells (PSCs) were treated with the vehicle control, DpC (10 mg/kg, three times/week via oral gavage), or Gemcitabine (Gem; 75 mg/kg, two times/week via intraperitoneal (i.p.) injection). Treatments were administered for 2 weeks, followed by 1 week recovery. Primary tumors were assessed for: NDRG1, TnC, β-catenin, and YAP/TAZ expression via immunohistochemistry (IHC; scale bar = 50 μm; 40×). Results are mean ± S.E.M (n = 7 mice; three images/specimen). ∗p < 0.05; ∗∗∗p < 0.001 comparing each treatment with the respective vehicle control (Con). ###p < 0.001 comparing DpC with Gem.